About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Many rare diseases of genetic origin affect neurodevelopment, causing severe motor problems that are difficult to treat. Our team uses a multidisciplinary approach to develop personalized treatments based on precision medicine with these objectives:
Our team promotes clinical and translational research in hospital care programs, such as units specialized in Dystonia and other Movement Disorders, Ataxias and Paraparesis, the Fetal Medicine Unit for Prenatal Diagnosis of Neurological Diseases and the Gene Therapy group for Neuromuscular pathology. Our researchers lead projects in the ERN-RND.
The application of advanced magnetic resonance imaging (MRI) techniques enables an objective and quantitative characterization of the progression of various neurological diseases. This research focuses on developing imaging biomarkers to identify radiological patterns. For neuromuscular diseases, the aim is to identify specific patterns of fat replacement and muscle inflammation, as well as to correlate these changes with motor function and other clinical parameters. For patients with movement disorders, specific imaging patterns will be studied to establish efficacy biomarkers for deep brain stimulation. This will contribute to better patient stratification and evaluation of responses to different experimental treatments.
IP: Belen Perez Dueñas, David Gómez Andrés
The objective of the line is to evaluate the added value of the information provided by quantitative MR techniques, mainly T1 and T2 relaxometry, as well as chemical exchange saturation transfer imaging (CEST) to the study of neurological and neuro-oncological diseases.
IP: Fco. Javier Aymerich Martínez, Alex Rovira Cañellas, Cristina Auger Acosta
IP: David Gómez Andrés Collaborators: - Funding agency: Duchenne Parent Project España Funding: 35100 Reference: DUCHENNE/AYUDAS/GOMEZ/2024 Duration: 27/02/2025 - 27/02/2027
IP: Begoña Benito Villabriga Collaborators: Carmen Escudero Iriarte, Laia Ventura i Expósito, Susana Otero Romero, Ignacio Ferreira González, José Antonio Barrabés Riu, Carlos Nos Llopis, Pablo Velasco Puyó, Jose Fernando Rodríguez Palomares, TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas, Belen Perez Dueñas, Jaume Sastre Garriga, Joan López Hellin, Antonia Sambola Ayala, Jordi Rio Izquierdo, Nuria Rivas Gandara, Jordi Perez Rodon, Aroa Soriano Fernández, Manuel Comabella Lopez, Antonio Rodríguez Sinovas, Gisela Teixido Tura, Antonia Pijuan Domenech, Roser Ferrer Costa, Joaquin Seras Franzoso, Carmen Tur Gomez, Maria Cristina Díaz de Heredia Rubio, Laia Yañez Bisbe, TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas, Miguel Segura Ginard, Diego Baranda Martínez-Abasca, Cristina Auger Acosta, Neus Bellera Gotarda, Teresa Macarulla Mercadé, Herena Eixarch Ahufinger, M Mar Mañu Pereira, Deborah Pareto Onghena, Lorena Valero Arrese, Aitor Uribarri Gonzalez, Jordi Bañeras Rius, Alex Rovira Cañellas, Mar Tintore Subirana, Bruno García del Blanco, Ana Vivancos Prellezo, Maria Teresa Salcedo Allende, Marisol Ruiz Meana, Ana Belén Méndez Fernández, TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas, Simon Schwartz Navarro, Anna Llort Sales, Carmen Espejo Ruiz, Raquel Hladun Alvaro, Sandra Mancilla Zamora, Ana Zabalza de Torres, Javier Inserte Igual, Luciana Midaglia Fernandez, Elizabeth Pando Rau, Gabriela Guillén Burrieza, Ana Laura Cazurro Gutierrez, David Gómez Andrés, Alvaro Cobo Calvo, Alvaro Calabuig Goena, Joaquin Castillo Justribo, Lydia Dux-Santoy Hurtado, Lucas Moreno Martín-Retortillo, Andres Miguez Gonzalez, Josep Roma Castanyer, Laura Dos Subirá, Nicolás Miguel Fissolo, Maria Nazarena Pizzi, Paolo Giovanni Nuciforo, Tian Tian, Diana Fernandes de Rafael, Andrea Guala Funding agency: Instituto de Salud Carlos III Funding: 2494527.53 Reference: FORT23/00034 Duration: 01/01/2024 - 31/12/2027
IP: Belen Perez Dueñas Collaborators: Maria Victoria Gonzalez Martinez, Anna Marcé Grau, Ana Laura Cazurro Gutierrez, Amaia Lasa Aranzasti Funding agency: Instituto de Salud Carlos III Funding: 125840 Reference: PI21/00248 Duration: 01/01/2022 - 30/06/2026
IP: Ariadna Laguna Tuset Collaborators: Maria Victoria Gonzalez Martinez, Miquel Vila Bover, Daniela Samaniego Toro, The brain-body axis in Parkinson’s disease patients: from pathophysiology to biomarkers and therapeutic approaches , Sara Belmonte Calderon Funding agency: Instituto de Salud Carlos III Funding: 171820 Reference: PI21/01603 Duration: 01/01/2022 - 30/06/2026
Over the course of one week, it will host in-person assessments for 35 families to better understand the progression of the disease and contribute to the development of new therapies.
The event focused on advances in disease-modifying therapies and on the value of alliances between patients and professionals to promote more participatory care and research.
The donation will enable further characterisation of patients with this rare disease, the identification of new biomarkers and the exploration of innovative therapies.
